Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Open access
Voorhees, Peter M, Sborov, Douglas W, Laubach, Jacob, Kaufman, Jonathan L, Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J, Anderson, Larry D, Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Efebera, Yvonne A, Holstein, Sarah A, Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M, Orlowski, Robert Z, Shain, Kenneth H, Cowan, Andrew J, Dinner, Shira, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S, Usmani, Saad Z, Richardson, Paul G · 2023 · The Lancet Haematology

Abstract

BACKGROUND Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma. Here, we report the findings of the predefined final analysis. METHODS GRIFFIN was an open-label, randomised, active-controlled, phase 2 trial done in 35 research centres in the USA. Patients had newly diagnosed multiple myeloma with measurable disease by M protein or free light chain, were aged 18-70 years, had an ECOG performance score of 0-2, and were eligible for autologous haematopoietic stem-cell transplantation (HSCT). Patients were randomly assigned (1:1) to four D-RVd or RVd induction cycles, autologous HSCT, two D-RVd or RVd consolidation cycles, and lenalidomide with or without daratumumab maintenance therapy for 2 years. Patients received 21-day cycles of oral lenalidomide (25 mg on days 1-14), subcutaneous bortezomib (1·3 mg/m2 on days 1, 4, 8, and 11), oral dexamethasone (40 mg weekly) with or without intravenous daratumumab (16 mg/kg weekly, cycles 1-4; day 1, cycles 5-6). Maintenance therapy (28-day cycles) was oral lenalidomide (10 mg on days 1-21) with or without daratumumab (16 mg/kg intravenously every 4 or 8 weeks, or 1800 mg subcutaneously monthly). Patients could continue lenalidomide maintenance after study treatment completion. The primary endpoint was stringent complete response rate by the end of consolidation in the response-evaluable population, and has already been reported. Here we report updated stringent complete response rates and secondary outcomes including progression-free survival and overall survival. The trial is registered with ClinicalTrials.gov (NCT02874742) and ended on April 8, 2022. FINDINGS Between Dec 20, 2016, and April 10, 2018, 104 patients were randomly assigned to the D-RVd group and 103 were randomly assigned to the RVd group; most patients were White (85 [82%] in the D-RVd group and 76 [74%] in the RVd group) and male (58 [56%] in the D-RVd group and 60 [58%] in the RVd group). At a median follow-up of 49·6 months (IQR 47·4-52·1), D-RVd improved rates of stringent complete response (67 [67%] of 100] vs 47 [48%] of 98]; odds ratio 2·18 [95% CI 1·22-3·89], p=0·0079), and 4-year progression-free survival was 87·2% (95% CI 77·9-92·8) for D-RVd versus 70·0% (95% CI 55·9-80·3) for RVd, with a hazard ratio (HR) of 0·45 (95% CI 0·21-0·95, p=0·032) for risk of disease progression or death with D-RVd. Median overall survival was not reached for either group (HR 0·90 [95% CI 0·31-2·56], p=0·84). The most common grade 3-4 treatment-emergent adverse events in the D-RVd versus RVd groups were neutropenia (46 [46%] of 99 vs 23 [23%] of 102), lymphopenia (23 [23%] vs 23 [23%]), leukopenia (17 [17%] vs eight [8%]), thrombocytopenia (16 [16%] vs nine [9%]), pneumonia (12 [12%] vs 14 [14%]), and hypophosphataemia (ten [10%] vs 11 [11%]). Serious treatment-emergent adverse events occurred in 46 (46%) of 99 patients in the D-RVd group and in 53 (52%) of 102 patients in the RVd group. One patient in each treatment group reported a treatment-emergent adverse event that resulted in death (bronchopneumonia in the D-RVd group; cause unknown in the RVd group); neither was related to study treatment. No new safety concerns occurred with maintenance therapy. INTERPRETATION Addition of daratumumab to RVd improved the depth of response and progression-free survival in transplantation-eligible patients with newly diagnosed multiple myeloma. These results justify further evaluation in phase 3 studies. FUNDING Janssen Oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(23)00217-x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 7

  1. Moreau, 2021, Lancet Oncol, 22, 1378, 10.1016/S1470-2045(21)00428-9 · DOI · Paper page
  2. Dimopoulos, 2021, Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Hemasphere, 5, e528
  3. Voorhees, 2020, Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial, Blood, 136, 936, 10.1182/blood.2020005288 · DOI · Paper page
  4. Chhabra, 2023, Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials, Transplant Cell Ther, 29, 174.e1, 10.1016/j.jtct.2022.11.029 · DOI
  5. Goldschmidt, 2022, Lancet Haematol, 9, e810, 10.1016/S2352-3026(22)00263-0 · DOI · Paper page
  6. Joseph, 2020, Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma, J Clin Oncol, 38, 1928, 10.1200/JCO.19.02515 · DOI · Paper page
  7. Richardson, 2018, Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting, Blood Cancer J, 8, 109, 10.1038/s41408-018-0141-0 · DOI · Paper page

Cited by

See all 166

Metadata

Authors
Voorhees, P. M., Sborov, D. W., Laubach, J., Kaufman, J. L., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., Nathwani, N., Shah, N., Bumma, N., Efebera, Y. A., Holstein, S. A., Costello, C., Jakubowiak, A., Wildes, T. M., Orlowski, R. Z., Shain, K. H., Cowan, A. J., Dinner, S., Pei, H., Cortoos, A., Patel, S., Lin, T. S., Usmani, S. Z., & Richardson, P. G.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2023-10
Volume
10
Issue
10
Pages
e825-e837
ISSN
2352-3026 (ISSN-L)
OpenAlex
W4386617910
Cited by
166
References
5
FWCI
29.58
Type
journal article
Language
en
Open access
green
Funders
  • National Comprehensive Cancer Network
  • Janssen Scientific Affairs LLC

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2352-3026(23)00217-x
The paper
Voorhees, P. M., Sborov, D. W., Laubach, J., Kaufman, J. L., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., Nathwani, N., Shah, N., Bumma, N., Efebera, Y. A., Holstein, S. A., Costello, C., Jakubowiak, A., Wildes, T. M., Orlowski, R. Z., . . . Richardson, P. G. (2023). Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(23)00217-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.